304 related articles for article (PubMed ID: 26867766)
1. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
2. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
4. Bladder tumor-targeted delivery of pro-apoptotic peptide for cancer therapy.
Jung HK; Kim S; Park RW; Park JY; Kim IS; Lee B
J Control Release; 2016 Aug; 235():259-267. PubMed ID: 27282414
[TBL] [Abstract][Full Text] [Related]
5. Tumor-penetrating iRGD peptide inhibits metastasis.
Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
[TBL] [Abstract][Full Text] [Related]
6. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
[TBL] [Abstract][Full Text] [Related]
7. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
[TBL] [Abstract][Full Text] [Related]
8. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
Cho HJ; Park SJ; Lee YS; Kim S
J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
[TBL] [Abstract][Full Text] [Related]
9. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
[TBL] [Abstract][Full Text] [Related]
10. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
11. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery.
Yin J; Liu D; Bao L; Wang Q; Chen Y; Hou S; Yue Y; Yao W; Gao X
Cancer Lett; 2019 Jun; 452():38-50. PubMed ID: 30904618
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
13. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
[TBL] [Abstract][Full Text] [Related]
14. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
15. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells.
Mao X; Liu J; Gong Z; Zhang H; Lu Y; Zou H; Yu Y; Chen Y; Sun Z; Li W; Li B; Gao J; Zhong Y
Nanomedicine (Lond); 2015; 10(17):2677-95. PubMed ID: 26355733
[TBL] [Abstract][Full Text] [Related]
16. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
17. A surface charge-switchable and folate modified system for co-delivery of proapoptosis peptide and p53 plasmid in cancer therapy.
Chen S; Rong L; Lei Q; Cao PX; Qin SY; Zheng DW; Jia HZ; Zhu JY; Cheng SX; Zhuo RX; Zhang XZ
Biomaterials; 2016 Jan; 77():149-63. PubMed ID: 26599622
[TBL] [Abstract][Full Text] [Related]
18. Cell penetrating peptides improve tumor delivery of cargos through neuropilin-1-dependent extravasation.
Kadonosono T; Yamano A; Goto T; Tsubaki T; Niibori M; Kuchimaru T; Kizaka-Kondoh S
J Control Release; 2015 Mar; 201():14-21. PubMed ID: 25592386
[TBL] [Abstract][Full Text] [Related]
19. Application of a proapoptotic peptide to intratumorally spreading cancer therapy.
Chen R; Braun GB; Luo X; Sugahara KN; Teesalu T; Ruoslahti E
Cancer Res; 2013 Feb; 73(4):1352-61. PubMed ID: 23248118
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
